drugset / Trial / NCT05582096
A Study of LY3457263 in Obese Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.
Timeline
- Start
- 2022-11-11
- Primary completion
- 2023-06-08
- Completion
- 2023-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NISOTIROSTIDE | Protein / enzyme biologic | — | Subcutaneous |
| Background | Tirzepatide | Peptide | — | Subcutaneous |